5-[[4-[(6-Hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 5-[[4-[(6-Hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride
• 化学式: C24H28ClNO5S
• 分子量: 478.0
• InChiKey: MPVULJFYAIGUFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP2070926A1

  公开（公告）日：2009-06-17

  The present invention provides 13,13a-dihydroberberine derivatives or their physiologically acceptable salts represented by the following formula, pharmaceutical compositions comprising the same, and uses thereof. The 13,13a-dihydroberberine derivatives have an activity of promoting glucose absorption in muscle cells, and the whole animal tests show that the present compounds have effects on improving glucose-tolerance and insulin-resistance, facilitating weight loss, relieving fatty liver and the like. Thus, the present compounds can be used in treating diabetes mellitus, adiposity, fatty liver and complications thereof induced by insulin resistance.

  本发明提供了由下式表示的13,13a-二氢小檗碱衍生物或其生理上可接受的盐、由其组成的药物组合物及其用途。13,13a-二氢小檗碱衍生物具有促进肌肉细胞吸收葡萄糖的活性，整体动物试验表明，本发明化合物具有改善糖耐量和胰岛素抵抗、促进减肥、缓解脂肪肝等作用。因此，本化合物可用于治疗胰岛素抵抗引起的糖尿病、肥胖症、脂肪肝及其并发症。
• Core formulation
  申请人：——

  公开号：US20010034374A1

  公开（公告）日：2001-10-25

  This invention relates to a controlled release combination drug product comprising troglitazone, e.g. its hydrochloride, and a biguamide, e.g. metformin. In particular, the product comprises a core of metformin, at least a portion thereof has a layer or coat thereon of troglitazone.

  本发明涉及一种由曲格列酮（如其盐酸盐）和双胍（如二甲双胍）组成的控释复合药物产品。特别是，该产品包括一个二甲双胍核心，其至少一部分具有曲格列酮层或外衣。
• Compositions and methods for the prevention and control of insulin-induced hypoglycemia
  申请人：Green T. Daniel

  公开号：US20060014670A1

  公开（公告）日：2006-01-19

  Pharmaceutical compositions comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.

  由胰岛素和胰高血糖素组成的药物组合物可用于控制和治疗糖尿病，同时降低或消除胰岛素诱发低血糖的风险。
• CORE FORMULATION COMPRISING TROGLITAZONE AND A BIGUANIDE
  申请人：Kos Life Sciences, Inc.

  公开号：EP1429740A1

  公开（公告）日：2004-06-23
• EP1429740A4
  申请人：——

  公开号：EP1429740A4

  公开（公告）日：2005-01-26